CAPTRUST Financial Advisors’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.95M Buy
11,566
+322
+3% +$55.6K ﹤0.01% 1236
2025
Q4
$2.05M Buy
11,244
+3,285
+41% +$459K ﹤0.01% 1083
2025
Q3
$967K Buy
7,959
+967
+14% +$109K ﹤0.01% 1447
2025
Q2
$730K Buy
6,992
+3,888
+125% +$412K ﹤0.01% 1507
2025
Q1
$362K Buy
3,104
+151
+5% +$17.2K ﹤0.01% 1837
2024
Q4
$250K Sell
2,953
-2,769
-48% -$255K ﹤0.01% 2017
2024
Q3
$514K Buy
+5,722
New +$499K ﹤0.01% 1559
2023
Q4
Sell
-2,881
Closed -$201K 2671
2023
Q3
$201K Buy
2,881
+30
+1% +$2.24K ﹤0.01% 2292
2023
Q2
$205K Buy
+2,851
New +$210K ﹤0.01% 2251
2022
Q3
Sell
-705
Closed -$27K 2236
2022
Q2
$27K Sell
705
-52
-7% -$1.65K ﹤0.01% 3186
2022
Q1
$31K Buy
757
+646
+582% +$20K ﹤0.01% 3114
2021
Q4
$4K Buy
111
+35
+46% +$1.29K ﹤0.01% 4158
2021
Q3
$3K Buy
76
+16
+27% +$624 ﹤0.01% 4112
2021
Q2
$4K Hold
60
﹤0.01% 3936
2021
Q1
$3K Hold
60
﹤0.01% 3889
2020
Q4
$5K Hold
60
﹤0.01% 2827
2020
Q3
$4K Buy
+60
New +$4.67K ﹤0.01% 2575
2020
Q2
Sell
-3,400
Closed -$190K 2844
2020
Q1
$190K Sell
3,400
-250
-7% -$20.4K ﹤0.01% 873
2019
Q4
$370K Buy
+3,650
New +$147K 0.01% 782

Other funds holding AXSM

CAPTRUST Financial Advisors's AXSM Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Axsome Therapeutics (AXSM) stake by 2.9% in Q1 2026, buying an estimated $55.6K and bringing the position to 11,566 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1236.

CAPTRUST Financial Advisors first reported a position in AXSM in Q4 2019 and has held it in 19 quarters since. The position peaked at $2.05M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • CAPTRUST Financial Advisors held 11,566 shares of Axsome Therapeutics worth $1.95M as of Q1 2026.
  • CAPTRUST Financial Advisors bought 322 Axsome Therapeutics shares in Q1 2026, an estimated $55.6K.
  • Axsome Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1236 holding.
  • CAPTRUST Financial Advisors first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 19 quarters since.
  • CAPTRUST Financial Advisors's Axsome Therapeutics position peaked at $2.05M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.